ArticleFrontiers in human neuroscience2026
Clinical and immunological correlates of elevated age-adjusted QAlb in anti-NMDAR encephalitis.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-NMDAR encephalitis is a common form of autoimmune encephalitis with marked clinical heterogeneity. The cerebrospinal fluid (CSF)/serum albumin quotient (QAlb) is a clinically accessible marker reflecting blood-CSF barrier (BCB) function. However, the clinical significance of elevated age-adjusted QAlb in anti-NMDAR encephalitis remains unclear. Methods: We retrospectively enrolled 103 patients with anti-NMDAR encephalitis and classified them into Elevated QAlb and Normal QAlb groups according to whether measured QAlb exceeded its age-adjusted upper reference limit (Qlim). Clinical features, paired serum-CSF findings, quantitative indices of intrathecal IgG synthesis, MRI/EEG findings, disease severity, and discharge outcomes were compared. Logistic regression, sensitivity analyses, Reibergram, and Spearman correlation analyses were performed. Results: Elevated age-adjusted QAlb was identified in 36 patients (35.0%). Compared with the Normal QAlb group, the Elevated QAlb group had higher proportions of male patients and prodromal headache, and showed higher CSF protein, CSF albumin, CSF IgG, IgG index (IgGI), and 24-h intrathecal IgG synthesis rate. Reibergram analysis showed that a higher proportion of patients in the Elevated QAlb group were above the Qlim(IgG) curve than in the Normal QAlb group [9/36 (25.0%) vs. 4/67 (6.0%), Conclusion: Elevated age-adjusted QAlb was associated with increased quantitative markers of total intrathecal IgG synthesis, but not with CSF anti-NMDAR antibody titers, acute disease severity, or short-term discharge outcomes. These findings support interpreting QAlb as an accessible CSF marker related to BCB function rather than as a standalone acute prognostic marker. The observed association with hippocampal MRI abnormalities was exploratory and requires independent validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.